Intellia Therapeutics.
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
- Reports this week
- 1
- Active events
- 3
- Connections
- 60
What's happening
Active this week
-
Intellia Therapeutics and BeyondSpring are identified as small-cap healthcare companies.Some support1 report
-
Intellia Therapeutics and BeyondSpring Inc. are identified as small-cap healthcare companies.Some support1 report
-
Intellia Therapeutics and Spyre Therapeutics, Inc. are identified as healthcare companies competing for investment.Some support1 report
One to three months ago
-
The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.Some support2 reports2 developments inside
-
Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.Some support1 report
-
Intellia Therapeutics announced it will present at a conference on September 4, 2026.Some support1 report
-
Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.Some support1 report1 development inside
Gone quiet
No new reports in 90+ days-
Both Wolfspeed and Intellia Therapeutics are facing market scrutiny from short sellers.Some support1 report
-
Intellia Therapeutics listed its stock on the Nasdaq exchange.Well supported9 reports
-
Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.Some support1 report
-
Intellia Therapeutics received a share upgrade from William Blair, while Bank of America reiterated a neutral rating on June 17, 2026.Some support1 report
-
Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.Some support6 reports
-
Intellia Therapeutics developed a new therapy for patients suffering from hereditary angioedema (HAE).Some support2 reports
-
Moderna and Intellia Therapeutics are clinical-stage biotech companies.Speculative1 report
-
Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.Some support2 reports
-
Cathie Wood invested in Intellia Therapeutics, a company based in Cambridge, Massachusetts.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Intellia Therapeutics this week
News at the entities that move Intellia Therapeutics most-
Nasdaq StructuralCeriBell, Inc. traded on the Nasdaq stock exchange and filed insider transactions with the SEC on July 2, 2026.Moves Intellia Therapeutics
-
FDA StructuralThe FDA approved a new manufacturing process for biosimilar by Alvotech, with Joseph McClellan serving as COO.Moves Intellia Therapeutics
-
Regeneron Pharmaceuticals OperationalAndrew J. Murphy has been appointed Co-Chief Scientific Officer at Regeneron Pharmaceuticals.Moves Intellia Therapeutics
-
Ark Invest TransactionalArk Invest, led by Cathie Wood, is buying shares of Meta ahead of its earnings report.Moves Intellia Therapeutics
-
Securities and Exchange Commission StructuralMultiple firms filed Form 13F with the SEC detailing buying, selling, and trimming positions in the Vanguard Total Stock Market ETF.Moves Intellia Therapeutics
-
William P. Blair TransactionalJefferies Financial Group initiated coverage of Suja Life, Inc., providing a buy rating and price objective as of July 18, 2026.Moves Intellia Therapeutics
Connections
The 18 strongest of 60, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Regeneron Pharmaceuticals Operational
Intellia and Regeneron are engaged in a formal collaboration to co-develop and co-promote the genome-editing candidate nex-z.
-
Nasdaq Structural
Intellia Therapeutics is formally listed and trades its stock on the Nasdaq exchange.
-
John Leonard Structural
John Leonard serves as the President and CEO of Intellia Therapeutics.
-
FDA Structural
The FDA provides mandatory regulatory oversight and approval for Intellia Therapeutics' drug candidates.
-
Ark Invest Transactional
Ark Invest has tracked and focused on Intellia Therapeutics, indicating investment interest in disruptive innovation.
-
CRISPR Therapeutics Operational
Two companies actively compete in the gene-editing space utilizing CRISPR/Cas9 technology.
-
Securities and Exchange Commission Structural
Intellia Therapeutics is subject to regulatory filings and oversight by the Securities and Exchange Commission.
-
OrbiMed Transactional
A secured a $400 million senior secured term loan facility.
Show all 18 connections
-
William P. Blair Transactional
William Blair upgraded his shares of Intellia Therapeutics.
-
Istanbul Shared context
Intellia Therapeutics is utilizing Istanbul as the location for its conference presentations, including the EAACI Annual Congress 2026.
-
Wolfspeed Mentioned together
Both companies were mentioned in the same article facing market scrutiny from short sellers.
-
TD Cowen Transactional
TD Cowen acted as the exclusive financial advisor for a transaction involving Intellia Therapeutics.
-
Citigroup Mentioned together
Citigroup publishes research reports and market ratings concerning Intellia Therapeutics.
-
Yahoo! Finance Mentioned together
Yahoo! Finance references market price targets related to Intellia Therapeutics' stock movement.
-
MarketBeat Mentioned together
MarketBeat provides average rating data for Intellia Therapeutics.
-
Cambridge Shared context
Intellia Therapeutics is located and operates from Cambridge, Massachusetts.
-
Bank of America Mentioned together
Bank of America provided an investment rating for Intellia Therapeutics.
-
Morgan Stanley Mentioned together
The provided evidence is insufficient to establish a coupled relationship between the two entities.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
10 events- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
- Intellia Therapeutics listed its stock on the Nasdaq exchange.
- Omeros partnered with Novo Nordisk on zaltenibart development, while Intellia and Regeneron formed a collaboration on co-developing therapies. Separately, the FDA approved Omeros' Yartemlea for TA-TMA treatment.
- Intellia Therapeutics received a share upgrade from William Blair, while Bank of America reiterated a neutral rating on June 17, 2026.
- Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.
- Intellia Therapeutics developed a new therapy for patients suffering from hereditary angioedema (HAE).
- Moderna and Intellia Therapeutics are clinical-stage biotech companies.
- Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.
- Cathie Wood invested in Intellia Therapeutics, a company based in Cambridge, Massachusetts.